Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients

Pfizer logo

Pfizer

Status

Completed

Conditions

Kidney Transplantation

Treatments

Drug: Tofacitinib

Study type

Observational

Funder types

Industry

Identifiers

NCT01375127
A3921053

Details and patient eligibility

About

This is an observational study designed to collect follow-up clinical date on subjects who were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or did not elect to enroll in long-term extension studies.

Full description

Subjects are identified based on whether they received tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or who did not elect to enroll in long-term extension studies. Subjects are pre-identified

Enrollment

83 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects have discontinued tofacitinib prior to the planned treatment duration in 2 completed Phase 2 studies; or have not enrolled in long-term extension studies.

Exclusion criteria

No other subjects are eligible for this study

Trial design

83 participants in 2 patient groups

Subjects from Study A3921009
Treatment:
Drug: Tofacitinib
Subjects from Study A3921030
Treatment:
Drug: Tofacitinib

Trial contacts and locations

43

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems